{"DataElement":{"publicId":"10404422","version":"1","preferredName":"Hematopoietic Cell Transplantation Disease or Disorder Indication Acute Lymphoblastic Leukemia Reason","preferredDefinition":"The specific indication for the hematopoietic cell transplantation for acute lymphoblastic leukemia.","longName":"HCT_IND_ALL_REA","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"10404358","version":"1","preferredName":"Hematopoietic Cell Transplantation Disease or Disorder Indication","preferredDefinition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","longName":"2659877v1.00:10404357v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2659877","version":"1","preferredName":"Stem Cell Transplantation","preferredDefinition":"A method of replacing the immature blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells.  The stem cells are given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.","longName":"C15431","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33BBDBD7-E7FD-4A2E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-25","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-06-25","modifiedBy":"ONEDATA","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"10404357","version":"1","preferredName":"Disease or Disorder Indication","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","longName":"C2991:C41184","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3221-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3222-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"10404371","version":"1","preferredName":"Acute Lymphoblastic Leukemia Hematopoietic Cell Transplantation Indication Reason","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication)._An explanation of the cause of some phenomenon or action.","longName":"10404371v1.00","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CR1 induction failure","valueDescription":null,"ValueMeaning":{"publicId":"10404407","version":"1","preferredName":"CR1 induction failure","longName":"10404407v1.00","preferredDefinition":"CR1 induction failure","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6BB-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6BE-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR1 with persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission","valueDescription":null,"ValueMeaning":{"publicId":"10404408","version":"1","preferredName":"CR1 with persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission","longName":"10404408v1.00","preferredDefinition":"CR1 with persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6BC-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6BF-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"Treated with CART cells for whom transplant is indicated transplant for consolidation","valueDescription":null,"ValueMeaning":{"publicId":"10404409","version":"1","preferredName":"Treated with CART cells for whom transplant is indicated transplant for consolidation","longName":"10404409v1.00","preferredDefinition":"Treated with CART cells for whom transplant is indicated transplant for consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6BD-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6C0-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR1 treatment failure as per MRD by flow cytometry >0.01% after consolidation","valueDescription":null,"ValueMeaning":{"publicId":"10404410","version":"1","preferredName":"CR1 treatment failure as per MRD by flow cytometry >0.01% after consolidation","longName":"10404410v1.00","preferredDefinition":"CR1 treatment failure as per MRD by flow cytometry >0.01% after consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC126EC-1DAF-3073-E053-731AD00A1C5A","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC126EC-1DB0-3073-E053-731AD00A1C5A","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"Loss of CART persistence and/or B cell aplasia < 6 months from infusion","valueDescription":null,"ValueMeaning":{"publicId":"10404411","version":"1","preferredName":"Loss of CART persistence and/or B cell aplasia < 6 months from infusion","longName":"10404411v1.00","preferredDefinition":"Loss of CART persistence and/or B cell aplasia < 6 months from infusion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6C4-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6C5-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR1 T cell ALL with persistent MRD > 0.01% after consolidation","valueDescription":null,"ValueMeaning":{"publicId":"10404412","version":"1","preferredName":"CR1 T cell ALL with persistent MRD > 0.01% after consolidation","longName":"10404412v1.00","preferredDefinition":"CR1 T cell ALL with persistent MRD > 0.01% after consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6C6-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6C7-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR3 or greater","valueDescription":null,"ValueMeaning":{"publicId":"10404413","version":"1","preferredName":"CR3 or greater","longName":"10404413v1.00","preferredDefinition":"CR3 or greater","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6C8-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6C9-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"Treated with CART and now has other evidence (e.g., MRD+) that transplant is indicated to prevent relapse","valueDescription":null,"ValueMeaning":{"publicId":"10466844","version":"1","preferredName":"Treated with CART and now has other evidence (e.g., MRD+) that transplant is indicated to prevent relapse","longName":"10466844v1.00","preferredDefinition":"Treated with CART and now has other evidence (e.g., MRD+) that transplant is indicated to prevent relapse","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E10A40FD-67E0-2FAB-E053-731AD00ACC4E","latestVersionIndicator":"Yes","beginDate":"2022-06-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-13","modifiedBy":"KUMMEROA","dateModified":"2022-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6CB-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-13","deletedIndicator":"No"},{"value":"CR2 T-cell or Ph+ BM relapse at any time","valueDescription":null,"ValueMeaning":{"publicId":"10404415","version":"1","preferredName":"CR2 T-cell or Ph+ BM relapse at any time","longName":"10404415v1.00","preferredDefinition":"CR2 T-cell or Ph+ BM relapse at any time","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6CC-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6CD-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR2 T or B cell end-Block 1 MRD ≥ 0.1%","valueDescription":null,"ValueMeaning":{"publicId":"10404416","version":"1","preferredName":"CR2 T or B cell end-Block 1 MRD ≥ 0.1%","longName":"10404416v1.00","preferredDefinition":"CR2 T or B cell end-Block 1 MRD ≥ 0.1%","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6CE-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6CF-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR2 T or B-cell early (<18 months) IEM (isolated early extramedullary relapse)","valueDescription":null,"ValueMeaning":{"publicId":"10404417","version":"1","preferredName":"CR2 T or B-cell early (<18 months) IEM (isolated early extramedullary relapse)","longName":"10404417v1.00","preferredDefinition":"CR2 T or B-cell early (<18 months) IEM (isolated early extramedullary relapse)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6D0-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6D1-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR2 B cell late BM relapse (≥ 36 months) with MRD > 0.1% by flow cytometry after first re-induction therapy","valueDescription":null,"ValueMeaning":{"publicId":"10404418","version":"1","preferredName":"CR2 B cell late BM relapse (≥ 36 months) with MRD > 0.1% by flow cytometry after first re-induction therapy","longName":"10404418v1.00","preferredDefinition":"CR2 B cell late BM relapse (≥ 36 months) with MRD > 0.1% by flow cytometry after first re-induction therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6D2-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6D3-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR2 B cell early (<36 months from initiation of therapy) BM relapse","valueDescription":null,"ValueMeaning":{"publicId":"10404419","version":"1","preferredName":"CR2 B cell early (<36 months from initiation of therapy) BM relapse","longName":"10404419v1.00","preferredDefinition":"CR2 B cell early (<36 months from initiation of therapy) BM relapse","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-B6D4-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-B6D5-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"CR 2 T or B cell late (≥ 18 months) IEM","valueDescription":null,"ValueMeaning":{"publicId":"10404421","version":"1","preferredName":"CR 2 T or B cell late (≥ 18 months) IEM","longName":"10404421v1.00","preferredDefinition":"CR 2 T or B cell late (≥ 18 months) IEM","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-55EF-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-55F0-2FB8-E053-731AD00AE15F","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-5790-2FB8-E053-731AD00AE15F","beginDate":"2022-06-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-02","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","deletedIndicator":"No"},{"value":"CR1 hypodiploidy (<44 chromosomes) with MRD greater than 0.01% after induction","valueDescription":null,"ValueMeaning":{"publicId":"10404423","version":"1","preferredName":"CR1 hypodiploidy (<44 chromosomes) with MRD greater than 0.01% after induction","longName":"10404423v1.00","preferredDefinition":"CR1 hypodiploidy (<44 chromosomes) with MRD great than 0.01% after induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-55F3-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"RCHEN","dateCreated":"2022-06-01","modifiedBy":"CCURATOR","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-5791-2FB8-E053-731AD00AE15F","beginDate":"2022-06-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-02","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"10404370","version":"1","preferredName":"Acute Lymphoblastic Leukemia Hematopoietic Cell Transplantation Indication Reason","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication)._An explanation of the cause of some phenomenon or action.","longName":"10404370v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-323C-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-323D-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the indication for the hematopoietic cell transplantation for acute lymphoblastic leukemia?","type":"Preferred Question Text","description":"What was the indication for the hematopoietic cell transplantation for acute lymphoblastic leukemia?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Select the specific indication for HCT:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-55F1-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}